Clinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease

Clinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease

Background: The beneficial outcomes of ezetimibe plus statin therapy are well-established in coronary artery disease, but these remain unknown in lower extremity artery disease (LEAD). Objectives: This study evaluated the efficacy of an intensified lipid-lowering strategy involving ezetimibe plus st...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoshihiro Iwasaki, MD, PhD, Takenobu Shimada, MD, PhD, Takefumi Kishimori, MD, Atsuyuki Wada, MD, PhD, Jumpei Koike, MD, Takehiro Matsumoto, MD, PhD, Takafumi Yagi, MD, Masaharu Okada, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:JACC: Advances
Subjects:
all-cause mortality
ezetimibe
LEAD
major lower limb amputation
statin
Online Access:http://www.sciencedirect.com/science/article/pii/S2772963X25004995
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The beneficial outcomes of ezetimibe plus statin therapy are well-established in coronary artery disease, but these remain unknown in lower extremity artery disease (LEAD). Objectives: This study evaluated the efficacy of an intensified lipid-lowering strategy involving ezetimibe plus statins vs statin monotherapy for reducing major adverse limb events and mortality in patients with LEAD. Methods: This retrospective analysis included patients aged ≥18 years diagnosed with LEAD from the TriNetX global health care database from 2013 to 2022, excluding those with recent acute coronary syndrome or stroke. The primary outcome was the 12-month cumulative incidence of major lower limb amputation and all-cause death as a composite endpoint. Propensity score matching was used to adjust for baseline characteristics and confounders, yielding 4,204 patients in each group. Results: The composite endpoint was lower with statins plus ezetimibe vs statin monotherapy (5.8% vs 10.2%; P < 0.001; HR: 0.54; 95% CI: 0.46-0.64). Taken individually, both major lower limb amputation (2.7% vs 4.6%; P < 0.001; HR: 0.57; 95% CI: 0.45-0.72) and all-cause death (3.4% vs 6.3%; P < 0.001; HR: 0.52; 95% CI: 0.42-0.65) were significantly lower with combination therapy. Subgroup analyses showed consistent effects across all subgroups. Conclusions: Compared to statin monotherapy, an intensified lipid-lowering strategy (ie, ezetimibe plus statins), significantly reduced the incidence of major lower limb amputation and all-cause mortality in real-world patients with LEAD.
ISSN:2772-963X

Similar Items